Daiichi Sankyo Co. Ltd. announced the discontinuation of the Phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in lung cancer.
The Phase 3 clinical trial was a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. Patients received either nimotuzumab in combination with concurrent chemoradiotherapy or a placebo in combination with concurrent chemoradiotherapy.
The study was discontinued based on the recent recommendation of the Independent Data Monitoring Committee which observed safety issues in certain patients who received a combination of cisplatin, vinorelbine, radiotherapy and nimotuzumab.
Date: April 25, 2014
Source: Daiichi Sankyo